You are tasked with generating a comprehensive MBBS Pharmacology PDF covering all major systems. Use Python with reportlab to create a professional, well-formatted PDF. ## Task Create a complete MBBS Pharmacology study PDF at: /home/daytona/workspace/mbbs-pharmacology/MBBS_Pharmacology_Complete.pdf ## Setup First run: mkdir -p /home/daytona/workspace/mbbs-pharmacology ## Requirements The PDF must cover ALL of the following systems with deep content: 1. **General Pharmacology** (pharmacokinetics, pharmacodynamics, drug-receptor interactions, dose-response) 2. **ANS - Autonomic Nervous System** (cholinergic, adrenergic, drugs affecting ANS) 3. **CNS - Central Nervous System** (sedative-hypnotics, antiepileptics, antipsychotics, antidepressants, opioids, local anesthetics, general anesthetics) 4. **CVS - Cardiovascular System** (antihypertensives, antiarrhythmics, heart failure drugs, anticoagulants, antiplatelets, thrombolytics, lipid-lowering) 5. **Renal / Diuretics** (loop, thiazide, potassium-sparing, osmotic, carbonic anhydrase inhibitors) 6. **Antimicrobials** (beta-lactams, aminoglycosides, macrolides, fluoroquinolones, tetracyclines, antifungals, antivirals, antiprotozoals, anthelmintics) 7. **Endocrine** (insulin, oral hypoglycemics, thyroid drugs, corticosteroids, sex hormones, contraceptives) ## Format for Each Section - Section title and overview - Mechanism of action (detailed) - Drug classification table - Key drugs with: receptor, MOA, uses, side effects, contraindications - Clinical pearl boxes - Mnemonic boxes - Exam Q&A section (5-10 MCQ-style questions with answers) ## PDF Generation Instructions Use Python with reportlab. Here is a complete working script template: ```python from reportlab.lib.pagesizes import A4 from reportlab.lib.styles import getSampleStyleSheet, ParagraphStyle from reportlab.lib.units import inch, cm from reportlab.lib.colors import HexColor, white, black, navy, blue from reportlab.platypus import SimpleDocTemplate, Paragraph, Spacer, Table, TableStyle, PageBreak, HRFlowable from reportlab.lib.enums import TA_CENTER, TA_LEFT, TA_JUSTIFY from reportlab.platypus.flowables import KeepTogether # Create the document doc = SimpleDocTemplate( '/home/daytona/workspace/mbbs-pharmacology/MBBS_Pharmacology_Complete.pdf', pagesize=A4, rightMargin=2*cm, leftMargin=2*cm, topMargin=2.5*cm, bottomMargin=2.5*cm, title='MBBS Pharmacology Complete Guide', author='Medical Education' ) styles = getSampleStyleSheet() # Define custom styles title_style = ParagraphStyle('Title', parent=styles['Title'], fontSize=28, textColor=HexColor('#1a3c5e'), spaceAfter=20, alignment=TA_CENTER, fontName='Helvetica-Bold') heading1_style = ParagraphStyle('H1', parent=styles['Heading1'], fontSize=20, textColor=HexColor('#1a3c5e'), spaceAfter=10, spaceBefore=20, fontName='Helvetica-Bold', borderPad=4) heading2_style = ParagraphStyle('H2', parent=styles['Heading2'], fontSize=15, textColor=HexColor('#2e6da4'), spaceAfter=8, spaceBefore=14, fontName='Helvetica-Bold') heading3_style = ParagraphStyle('H3', parent=styles['Heading3'], fontSize=12, textColor=HexColor('#1a5276'), spaceAfter=6, spaceBefore=10, fontName='Helvetica-Bold') body_style = ParagraphStyle('Body', parent=styles['Normal'], fontSize=10, leading=15, spaceAfter=6, alignment=TA_JUSTIFY, fontName='Helvetica') bullet_style = ParagraphStyle('Bullet', parent=styles['Normal'], fontSize=10, leading=14, spaceAfter=3, leftIndent=20, firstLineIndent=0, fontName='Helvetica', bulletIndent=10) clinical_style = ParagraphStyle('Clinical', parent=styles['Normal'], fontSize=10, leading=14, spaceAfter=6, leftIndent=10, rightIndent=10, backColor=HexColor('#e8f4fd'), borderColor=HexColor('#2e6da4'), borderWidth=1, borderPad=6, fontName='Helvetica') mnemonic_style = ParagraphStyle('Mnemonic', parent=styles['Normal'], fontSize=10, leading=14, spaceAfter=6, leftIndent=10, rightIndent=10, backColor=HexColor('#fef9e7'), borderColor=HexColor('#f39c12'), borderWidth=1, borderPad=6, fontName='Helvetica') qa_q_style = ParagraphStyle('QAQ', parent=styles['Normal'], fontSize=10, leading=14, spaceAfter=3, leftIndent=10, fontName='Helvetica-Bold', textColor=HexColor('#1a3c5e')) qa_a_style = ParagraphStyle('QAA', parent=styles['Normal'], fontSize=10, leading=14, spaceAfter=8, leftIndent=20, fontName='Helvetica', textColor=HexColor('#196f3d')) def make_table(data, col_widths=None, header_color=HexColor('#1a3c5e')): if col_widths is None: col_widths = [3*cm] * len(data[0]) t = Table(data, colWidths=col_widths, repeatRows=1) style = TableStyle([ ('BACKGROUND', (0,0), (-1,0), header_color), ('TEXTCOLOR', (0,0), (-1,0), white), ('FONTNAME', (0,0), (-1,0), 'Helvetica-Bold'), ('FONTSIZE', (0,0), (-1,0), 9), ('ALIGN', (0,0), (-1,-1), 'LEFT'), ('VALIGN', (0,0), (-1,-1), 'TOP'), ('FONTNAME', (0,1), (-1,-1), 'Helvetica'), ('FONTSIZE', (0,1), (-1,-1), 8.5), ('ROWBACKGROUNDS', (0,1), (-1,-1), [HexColor('#f8f9fa'), white]), ('GRID', (0,0), (-1,-1), 0.5, HexColor('#bdc3c7')), ('TOPPADDING', (0,0), (-1,-1), 4), ('BOTTOMPADDING', (0,0), (-1,-1), 4), ('LEFTPADDING', (0,0), (-1,-1), 5), ('RIGHTPADDING', (0,0), (-1,-1), 5), ]) t.setStyle(style) return t def clinical_pearl(text): return Paragraph(f'<b>Clinical Pearl:</b> {text}', clinical_style) def mnemonic_box(text): return Paragraph(f'<b>Mnemonic:</b> {text}', mnemonic_style) def qa_block(questions): # questions = list of (question, answer) tuples items = [] for i, (q, a) in enumerate(questions, 1): items.append(Paragraph(f'Q{i}. {q}', qa_q_style)) items.append(Paragraph(f'Ans: {a}', qa_a_style)) return items ``` ## Content to Include Write comprehensive, accurate MBBS-level pharmacology content. Here is the full content to generate for each section: --- ### SECTION 1: GENERAL PHARMACOLOGY **Pharmacokinetics (ADME):** - Absorption: passive diffusion, active transport, first-pass effect, bioavailability (F = AUC oral/AUC IV x 100) - Distribution: Vd = Dose/Cp; protein binding; blood-brain barrier - Metabolism: Phase I (oxidation, CYP450) and Phase II (conjugation, glucuronidation); first-pass metabolism - Excretion: renal clearance; GFR, tubular secretion, reabsorption; Henderson-Hasselbalch for ionization - Half-life: t1/2 = 0.693 × Vd / CL; 5 half-lives to reach steady state - Zero order vs first order kinetics **Pharmacodynamics:** - Drug-receptor interactions: agonist, antagonist, partial agonist, inverse agonist - EC50, Emax, efficacy vs potency - Competitive vs non-competitive antagonism - Receptor types: G-protein coupled (Gs, Gi, Gq), ligand-gated ion channels, enzyme-linked, nuclear - Therapeutic index: TI = TD50/ED50; narrow TI drugs (lithium, digoxin, warfarin, aminoglycosides) **Drug interactions:** induction, inhibition of CYP450; additive, synergistic, antagonistic **Tables to include:** - CYP450 inducers vs inhibitors - Receptor types and second messengers - Narrow therapeutic index drugs --- ### SECTION 2: ANS PHARMACOLOGY **Overview:** - Sympathetic: preganglionic (ACh → nicotinic N1 receptors) → postganglionic (NE → α/β receptors) - Parasympathetic: preganglionic (ACh → N1) → postganglionic (ACh → muscarinic M1-M5) - Adrenal medulla: releases 80% epinephrine + 20% NE directly into blood **Cholinergic System:** - Synthesis: Choline + Acetyl-CoA → ACh (enzyme: ChAT) - Release: vesicle exocytosis (Ca2+ dependent); blocked by botulinum toxin - Termination: AChE breaks ACh → choline + acetate - Nicotinic receptors: N1 (ganglia, adrenal medulla), NM (neuromuscular junction) - Muscarinic receptors: M1 (CNS, gastric), M2 (heart - decreases HR), M3 (smooth muscle, glands), M4/M5 (CNS) **Cholinergic drugs (direct agonists):** - Acetylcholine: prototype; all receptors; rapid hydrolysis; not used clinically - Carbachol: not hydrolyzed by AChE; used in glaucoma - Bethanechol: selective M3; used for urinary retention, GERD; not hydrolyzed - Pilocarpine: alkaloid; used in glaucoma, Sjogren syndrome (promotes salivation) - Muscarine: M receptor; not clinically used; mushroom toxin **Anticholinesterases (indirect agonists):** - Reversible: Physostigmine (crosses BBB - antidote for atropine/anticholinergic overdose), Neostigmine (does NOT cross BBB - reversal of NMJ blockade, myasthenia gravis), Pyridostigmine (myasthenia gravis), Edrophonium (Tensilon test for MG diagnosis) - Irreversible: Organophosphates (nerve agents, insecticides); SLUDGE toxidrome; antidote: atropine + pralidoxime (2-PAM, within 24-48h before aging) **Muscarinic Antagonists (Anticholinergics):** - Atropine: prototype; competitive M antagonist; tachycardia, mydriasis, dry mouth, urinary retention, constipation, hyperthermia; antidote for organophosphate poisoning; used in bradycardia - Scopolamine: motion sickness; transdermal patch - Ipratropium/Tiotropium: inhaled; COPD/asthma; does NOT cross BBB - Oxybutynin/Tolterodine: overactive bladder (M3 antagonists) - Benztropine/Trihexyphenidyl: Parkinson disease **Ganglionic Blockers:** Trimethaphan (rarely used), Mecamylamine **Nicotinic (NM) Blockers - Neuromuscular Junction:** - Depolarizing: Succinylcholine (phase I block → fasciculations then paralysis; prolonged in pseudocholinesterase deficiency; malignant hyperthermia risk) - Non-depolarizing: Vecuronium, Rocuronium, Pancuronium, Atracurium; reversed by neostigmine + atropine (or sugammadex for rocuronium) **Adrenergic System:** - Tyrosine → DOPA (tyrosine hydroxylase, rate-limiting) → Dopamine → NE → Epinephrine - Reuptake (NET/uptake 1) - terminated by cocaine/TCAs - MAO (intraneuronal) and COMT (extraneuronal) metabolism **Adrenergic Receptors:** - α1: vasoconstriction (Gq → PLC → IP3/DAG → Ca2+), mydriasis, urinary sphincter contraction - α2: presynaptic (Gi → ↓cAMP → ↓NE release); postsynaptic: ↓insulin secretion - β1: heart (Gs → ↑cAMP → PKA → ↑HR, ↑contractility), kidney (↑renin) - β2: bronchodilation, vasodilation, glycogenolysis, uterine relaxation (Gs → ↑cAMP) - β3: lipolysis **Sympathomimetics:** - Epinephrine: α1+α2+β1+β2; used in anaphylaxis (IM), cardiac arrest (IV), status asthmaticus, with local anesthetics - Norepinephrine: α1+α2+β1 (minimal β2); vasopressor in septic shock - Dopamine (dose-dependent): low dose (1-5 mcg/kg/min) D1 → ↑renal blood flow; medium (5-10) β1 → ↑cardiac output; high (>10) α1 → vasoconstriction - Dobutamine: β1 selective; heart failure (inotrope) - Isoproterenol: β1+β2; bronchodilator, AV block - Salbutamol/Albuterol: β2 selective; asthma (SABA) - Salmeterol/Formoterol: β2 long-acting (LABA); asthma maintenance - Phenylephrine: α1 selective; nasal decongestant, hypotension during spinal anesthesia - Clonidine: α2 agonist; antihypertensive; also used in ADHD, opioid withdrawal **Adrenergic Blockers:** - α1 blockers: Prazosin, Doxazosin, Terazosin → HTN + BPH; first-dose orthostatic hypotension - α blockers (non-selective): Phentolamine (reversible), Phenoxybenzamine (irreversible) → pheochromocytoma - β1 selective: Metoprolol, Atenolol, Bisoprolol → HTN, angina, post-MI, heart failure - Non-selective β: Propranolol → HTN, angina, arrhythmias, thyroid storm, essential tremor, migraine prophylaxis; Timolol → glaucoma - α+β blocker: Carvedilol (heart failure), Labetalol (HTN in pregnancy) **Mnemonics:** - SLUDGE (organophosphate toxidrome): Salivation, Lacrimation, Urination, Defecation, GI cramps, Emesis - "ABCDE" receptors: α1-Arteries, β1-Brain(heart), β2-Breathing(bronchi) --- ### SECTION 3: CNS PHARMACOLOGY **Sedative-Hypnotics:** - Benzodiazepines (BZDs): positive allosteric modulators of GABA-A (↑Cl- influx → ↑frequency of Cl- channel opening); anxiolytic, sedative, anticonvulsant, muscle relaxant; examples: Diazepam, Lorazepam, Alprazolam, Midazolam, Clonazepam; antidote: Flumazenil; risk: respiratory depression, tolerance, dependence - Barbiturates: also at GABA-A but ↑duration of Cl- channel opening; more dangerous (no ceiling effect); Phenobarbital (epilepsy), Thiopental (IV anesthesia); strong CYP inducers - Zolpidem (Z-drugs): BZD receptor, but Z-hypnotic; less anticonvulsant/muscle relaxant; used for insomnia - Buspirone: 5-HT1A partial agonist; anxiolytic; no sedation, no dependence; 2-3 weeks onset; does not potentiate alcohol **Antiepileptics:** Table: Drug, MOA, Types of epilepsy, Adverse effects - Phenytoin: Na+ channel blocker; generalized tonic-clonic, focal; gingival hyperplasia, hirsutism, nystagmus, folic acid deficiency, teratogen (fetal hydantoin syndrome), zero-order kinetics - Carbamazepine: Na+ channel blocker; tonic-clonic, focal, trigeminal neuralgia; SIADH, aplastic anemia, teratogen (neural tube defects); CYP inducer; Steven-Johnson syndrome - Valproic acid: Na+ channel + GABA ↑ + T-type Ca2+ (absence); broad spectrum; hepatotoxicity, neural tube defects (spina bifida), weight gain, pancreatitis; inhibits CYP - Ethosuximide: T-type Ca2+ channel blocker; absence seizures ONLY (drug of choice) - Lamotrigine: Na+ channel; broad spectrum; Steven-Johnson syndrome; safe in pregnancy (relatively) - Levetiracetam: SV2A protein; broad spectrum; safest profile; minimal interactions - Gabapentin/Pregabalin: α2δ Ca2+ channel; neuropathic pain, epilepsy, fibromyalgia - Topiramate: Na+ channel + GABA; weight loss; kidney stones; cognitive side effects ("dopamax") - Benzodiazepines: acute seizures, status epilepticus (first line: Lorazepam IV or Diazepam PR) **Antipsychotics:** - Typical (FGAs): D2 receptor blockade; Chlorpromazine (low potency), Haloperidol (high potency); extrapyramidal side effects (EPS): akathisia, dystonia, parkinsonism, tardive dyskinesia; neuroleptic malignant syndrome (NMS) - Atypical (SGAs): D2 + 5-HT2 blockade; Clozapine (agranulocytosis - weekly CBC), Olanzapine, Risperidone, Quetiapine, Aripiprazole (D2 partial agonist); metabolic syndrome; less EPS - EPS treatment: acute dystonia → diphenhydramine or benztropine; NMS → dantrolene + bromocriptine - Mnemonic for clozapine: "Clozapine Causes Agranulocytosis" - check CBC weekly **Antidepressants:** - SSRIs (first line): Fluoxetine, Sertraline, Paroxetine, Citalopram, Escitalopram; serotonin syndrome risk; sexual dysfunction; weight gain; safe in pregnancy (Sertraline preferred) - SNRIs: Venlafaxine, Duloxetine; used for depression + neuropathic pain - TCAs: Amitriptyline, Imipramine; block NE + 5-HT reuptake + anticholinergic + antihistaminic; cardiotoxic (QRS widening → sodium bicarb treatment for overdose); used for neuropathic pain, bed-wetting (Imipramine) - MAOIs: Phenelzine, Tranylcypromine; irreversible; avoid tyramine foods (cheese, wine) → hypertensive crisis; serotonin syndrome with serotonergic drugs - Bupropion: NE+DA reuptake inhibitor; no sexual dysfunction; lowers seizure threshold; used for smoking cessation; do NOT use in eating disorders/seizure history - Mirtazapine: α2 antagonist + 5-HT2/3 blocker; sedating; weight gain; useful in elderly **Opioid Analgesics:** - MOA: μ (mu), κ (kappa), δ (delta) receptors (Gi coupled) → ↓cAMP, ↑K+ efflux, ↓Ca2+ influx → ↓neuronal excitability - Morphine: prototype; strong μ agonist; constipation, respiratory depression, miosis, euphoria, nausea; active metabolite morphine-6-glucuronide; avoid in renal failure - Codeine: prodrug → morphine (CYP2D6); antitussive - Tramadol: weak μ agonist + SNRI; serotonin syndrome risk; seizures - Fentanyl: 100x more potent than morphine; transdermal patch, IV; rapid onset - Methadone: long-acting μ agonist; opioid dependence treatment; QT prolongation - Buprenorphine: partial μ agonist + κ antagonist; ceiling effect on respiratory depression; opioid dependence (Suboxone = buprenorphine + naloxone) - Naloxone: opioid antagonist; antidote for overdose (IV/IM/intranasal); short acting (repeated doses needed) - Naltrexone: oral opioid antagonist; opioid + alcohol dependence maintenance **Local Anesthetics:** - MOA: block Na+ channels (voltage-gated) preferentially in depolarized/open state; block order: small unmyelinated C fibers > Aδ > Aβ > Aα (pain and temperature before pressure and motor) - Esters: cocaine (vasoconstriction), procaine, benzocaine, tetracaine; metabolized by plasma pseudocholinesterase; higher allergy risk - Amides: lidocaine, bupivacaine, ropivacaine, mepivacaine; metabolized by liver CYP enzymes; "i" before "-caine" = amide - Toxicity: CNS (tingling, seizures) and cardiac (arrhythmias, ↑PR/QRS); bupivacaine most cardiotoxic; treatment: lipid emulsion therapy (Intralipid) - Epinephrine added to prolong action and reduce systemic toxicity; NOT used in digits/nose/ears/penis (ring block areas) **General Anesthesia:** - Inhalational: MAC (minimum alveolar concentration) = measure of potency; agents: sevoflurane, isoflurane, desflurane, nitrous oxide; halothane → hepatotoxicity; malignant hyperthermia (succinylcholine/inhalational agents → dantrolene treatment) - IV induction: Propofol (most common; "milk of anesthesia"; GABA-A; pain on injection; PRIS), Ketamine (NMDA antagonist; dissociative; bronchodilator; increases HR/BP; emergence delirium; used in asthma, trauma), Etomidate (cardiovascular stable; adrenal suppression), Thiopental (barbiturate; rapid; ↑ICP contraindication) --- ### SECTION 4: CVS PHARMACOLOGY **Antihypertensives:** Blood pressure classification table (provided above from Lippincott): - Normal <120/80, Stage 1: 130-139/80-89, Stage 2: ≥140/90 Drug classes: - ACE Inhibitors: Captopril, Enalapril, Lisinopril, Ramipril; block ACE → ↓Angiotensin II → ↓aldosterone → ↓Na/H2O retention + vasodilation; also ↑bradykinin (→ dry cough, angioedema); contraindications: pregnancy (teratogenic), bilateral renal artery stenosis, hyperkalemia; preferred in diabetic nephropathy, heart failure, post-MI - ARBs: Losartan, Valsartan, Candesartan; AT1 receptor blockers; similar to ACEi but NO cough; preferred when ACEi cough is intolerable; also renoprotective - β-blockers: see ANS section; first-line HTN + angina + post-MI + heart failure (metoprolol, bisoprolol, carvedilol) - Ca2+ channel blockers: Dihydropyridines (Nifedipine, Amlodipine) - vascular selective, peripheral vasodilation, reflex tachycardia; Non-DHPs (Verapamil, Diltiazem) - also reduce HR/contractility; used in HTN + angina + arrhythmias; Verapamil constipation - Thiazide diuretics: Hydrochlorothiazide, Chlorthalidone; first-line HTN in uncomplicated patients; hypokalemia, hyponatremia, hypercalcemia, hyperuricemia, hyperglycemia; avoid in gout, diabetes - α1 blockers: Prazosin, Doxazosin → HTN + BPH; first-dose orthostatic hypotension - Central α2 agonists: Methyldopa (preferred in pregnancy), Clonidine (rebound HTN on abrupt withdrawal) - Vasodilators: Hydralazine (arteriolar; used in hypertensive emergency in pregnancy with methyldopa; drug-induced lupus), Minoxidil (hirsutism side effect; opens K+ channels), Nitroprusside (arterial + venous; hypertensive emergency; cyanide toxicity with prolonged use → treat with sodium thiosulfate or hydroxocobalamin) **Anti-anginal Drugs:** - Nitrates: Organic nitrates → NO → ↑cGMP → ↓Ca2+ → smooth muscle relaxation → venodilation (↓preload) + arteriodilation at high doses; Sublingual nitroglycerin (acute attack, rapid onset, 5 min), ISDN, ISMN (prophylaxis), Nitrate tolerance (nitrate-free interval needed); headache, flushing, hypotension; contraindicated with PDE5 inhibitors (sildenafil) - β-blockers: reduce O2 demand (↓HR, ↓contractility, ↓BP); stable angina - CCBs: diltiazem/verapamil (stable + vasospastic angina); nifedipine (vasospastic = Prinzmetal's angina) - Ranolazine: late Na+ channel inhibitor; stable angina; does not affect HR or BP; prolongs QT **Antiarrhythmic Drugs (Vaughan-Williams Classification):** - Class I (Na+ channel blockers): - IA: Quinidine, Procainamide, Disopyramide → ↑AP duration, ↑QT; used for atrial fibrillation, VT - IB: Lidocaine, Mexiletine → ↓AP duration; used for ventricular arrhythmias; post-MI - IC: Flecainide, Propafenone → no change in AP duration; used for SVT, AF; contraindicated post-MI (proarrhythmic) - Class II (β-blockers): Metoprolol, Propranolol → ↓HR, ↓AV conduction; AF rate control, SVT, post-MI - Class III (K+ channel blockers): ↑AP duration, ↑QT - Amiodarone: multi-class (I+II+III+IV); most effective; thyroid (hypo/hyperthyroid), pulmonary fibrosis, liver toxicity, corneal microdeposits, photosensitivity, blue-gray skin; drug interactions (inhibits CYP2C9 - warfarin levels ↑) - Sotalol: also β-blocker; AF; torsades de pointes risk - Ibutilide: IV; acute AF/flutter - Dofetilide: AF; strict monitoring - Class IV (CCBs): Verapamil, Diltiazem → AF rate control, SVT - Other: Adenosine (IV; termination of SVT; very short half-life 10 sec; causes transient AV block; flush, chest pain, bronchospasm; do not use in asthma); Digoxin (vagal effect → ↑AV block; used in AF rate control + heart failure with reduced EF; narrow TI; toxicity: GI + visual disturbances + arrhythmias; antidote: Digibind/DigiFab) - Mnemonic for amiodarone toxicity: "PALE SKIN" - Pulmonary fibrosis, Ataxia/atrial fibrillation, Liver toxicity, Eyes (corneal deposits), Skin (photosensitivity, blue-gray), Kidney (no direct), Iodine-rich (thyroid) **Heart Failure Drugs:** - ACEi/ARBs: reduce afterload + preload + cardiac remodeling; foundational therapy - β-blockers (Carvedilol, Metoprolol, Bisoprolol): reduce mortality in HFrEF; start low, go slow - Diuretics: loop diuretics for congestion (symptom relief) - Aldosterone antagonists: Spironolactone, Eplerenone; reduce mortality; hyperkalemia risk - SGLT2 inhibitors: Dapagliflozin, Empagliflozin; reduce hospitalization and mortality in HF (both preserved and reduced EF) - Sacubitril/Valsartan (Entresto): neprilysin inhibitor + ARB; superior to ACEi in HFrEF; do NOT combine with ACEi (angioedema risk) - Digoxin: positive inotrope; reduces hospitalization; no mortality benefit; use with low EF + AF - Ivabradine: If channel blocker; ↓HR; HFrEF with HR>70 on max β-blocker **Anticoagulants:** - Heparin (UFH): activates antithrombin III → inhibits IIa (thrombin) + Xa; IV/SC; monitored by aPTT; antidote: Protamine sulfate; HIT (heparin-induced thrombocytopenia) - occurs 5-10 days after starting heparin; type II is immune-mediated (IgG against PF4-heparin complex) → thrombosis; treat with direct thrombin inhibitor (argatroban, bivalirudin); NEVER re-challenge with heparin - LMWH (Enoxaparin): primarily anti-Xa; SC once/twice daily; predictable; does NOT require routine monitoring; preferred in pregnancy; partially reversed by protamine - Fondaparinux: selective anti-Xa; SC; no HIT risk; no antidote - Warfarin: Vitamin K antagonist (inhibits factors II, VII, IX, X and protein C, S); oral; monitored by INR; slow onset (2-3 days); interactions: many drugs; antidote: Vitamin K (slow) or Fresh Frozen Plasma (immediate) - Direct oral anticoagulants (DOACs): Dabigatran (anti-IIa; antidote Idarucizumab), Rivaroxaban/Apixaban/Edoxaban (anti-Xa; antidote Andexanet alfa); no routine monitoring; better bleeding profile than warfarin except in valvular AF/mechanical valves - Thrombolytics: Alteplase (tPA), Tenecteplase, Streptokinase; convert plasminogen to plasmin → fibrinolysis; acute MI (when PCI not available), acute ischemic stroke (within 4.5h), massive PE; major contraindication: recent surgery/bleeding, hemorrhagic stroke **Antiplatelets:** - Aspirin: irreversible COX inhibitor; antiplatelet + anti-inflammatory + antipyretic; low-dose (75-325 mg) for antiplatelet; high-dose GI bleeding risk - ADP receptor antagonists (P2Y12): Clopidogrel (prodrug, CYP2C19 activation), Prasugrel, Ticagrelor; used with aspirin (dual antiplatelet therapy) in ACS/PCI - GPIIb/IIIa inhibitors: Abciximab, Tirofiban, Eptifibatide; IV; PCI, ACS - Dipyridamole: phosphodiesterase inhibitor + adenosine uptake; used with aspirin (Aggrenox) for stroke prevention; coronary vasodilator (pharmacologic stress test) **Lipid-lowering Drugs:** - Statins: HMG-CoA reductase inhibitors; ↓LDL; side effects: myopathy, rhabdomyolysis (↑with gemfibrozil); contraindicated in pregnancy; first-line for CV risk - Ezetimibe: blocks NPC1L1 in gut → ↓cholesterol absorption; added to statins; no major side effects - PCSK9 inhibitors: Alirocumab, Evolocumab; injectable; dramatically ↓LDL; very expensive; used in familial hypercholesterolemia or statin intolerance - Fibrates: Gemfibrozil, Fenofibrate; ↓triglycerides, ↑HDL; PPARα agonists; myopathy with statins - Niacin (nicotinic acid): ↑HDL (most effective); flushing (prevented by aspirin pre-treatment); hyperglycemia, hyperuricemia; no CV mortality benefit proven - Bile acid sequestrants: Cholestyramine, Colestipol; bind bile acids → ↑LDL clearance; GI side effects; ↓absorption of fat-soluble vitamins + other drugs --- ### SECTION 5: RENAL PHARMACOLOGY / DIURETICS **Overview of Nephron Sites:** - PCT: Acetazolamide (CA inhibitor) - Thick ascending limb: Loop diuretics (furosemide, bumetanide, torsemide) - DCT: Thiazides (HCTZ, chlorthalidone) - Collecting duct: K-sparing (spironolactone, amiloride, triamterene) - Entire tubule: Osmotic diuretics (mannitol) **Loop Diuretics:** - Furosemide, Bumetanide, Torsemide, Ethacrynic acid - MOA: Block Na-K-2Cl cotransporter (NKCC2) in thick ascending LOH → ↓NaCl reabsorption → massive diuresis - Pharmacokinetics: IV furosemide → onset within minutes; oral → 30-60 min; can be given in renal failure (↑dose needed) - Uses: Pulmonary edema (1st line), edematous states (CHF, cirrhosis, nephrotic syndrome), hypercalcemia, hypertensive emergency, SIADH - Side effects (OHHHH): Ototoxicity (↑with aminoglycosides), Hypokalemia, Hyponatremia, Hypocalcemia, Hypochloremic metabolic alkalosis, Hyperuricemia (competes with uric acid for secretion), Hyperglycemia - Ethacrynic acid: only loop diuretic usable in sulfa allergy (NOT a sulfonamide) **Thiazide Diuretics:** - Hydrochlorothiazide (HCTZ), Chlorthalidone, Indapamide, Metolazone - MOA: Block NaCl cotransporter (NCC) in DCT - Uses: Hypertension (1st line in uncomplicated), heart failure (mild), nephrogenic diabetes insipidus (paradoxically ↓urine volume), calcium-containing kidney stones (↑Ca reabsorption), osteoporosis prevention - Side effects: Hypokalemia, Hyponatremia, Hypercalcemia (opposite of loop!), Hyperglycemia, Hyperuricemia, Hyperlipidemia; "GLUC-HI" mnemonic - Contraindicated in: gout, pregnancy, hypokalemia **Potassium-Sparing Diuretics:** - Spironolactone/Eplerenone: aldosterone antagonists → block mineralocorticoid receptor → ↓ENaC expression → ↓Na+ reabsorption, ↑K+ retention; side effects: hyperkalemia, gynecomastia (spironolactone - anti-androgen effect); used in primary hyperaldosteronism, heart failure (with ACEi/ARB, but monitor K+), ascites (liver cirrhosis) - Amiloride/Triamterene: directly block ENaC (epithelial Na+ channel) in collecting duct; K+ sparing; used to counteract K+ loss from loop/thiazide diuretics **Carbonic Anhydrase Inhibitors:** - Acetazolamide: inhibits CA in PCT → ↓HCO3- reabsorption → metabolic acidosis + alkaline urine; weak diuretic; used for: glaucoma (↓aqueous humor), altitude sickness (metabolic acidosis stimulates breathing), metabolic alkalosis, epilepsy (adjunct) - Side effects: metabolic acidosis, hypokalemia, paresthesias, renal stones (calcium oxalate, due to alkaline urine) **Osmotic Diuretics:** - Mannitol: filtered at glomerulus, not reabsorbed → osmotic force → ↑water in tubule → diuresis; used to ↓ICP (cerebral edema), ↓IOP (acute angle-closure glaucoma), prevent acute renal failure during cardiovascular surgery; contraindicated in pulmonary edema (initially ↑plasma osmolality → transient volume expansion) **ADH (Vasopressin) and antagonists:** - ADH/Vasopressin: V2 receptors in collecting duct → ↑AQP2 water channels → ↑water reabsorption - Desmopressin: V2 agonist; central DI, hemophilia A (↑vWF and Factor VIII), von Willebrand disease type 1 - Vasopressin V2 antagonists (Vaptans): Tolvaptan, Conivaptan; aquaretics (free water loss); used for euvolemic/hypervolemic hyponatremia (SIADH) --- ### SECTION 6: ANTIMICROBIALS **Beta-Lactam Antibiotics:** - MOA: Inhibit transpeptidase (PBP = penicillin-binding protein) → prevent peptidoglycan cross-linking → cell wall weakness → bacterial lysis; bactericidal; time-dependent killing - Penicillins: Penicillin G/V (gram+ organisms, streptococci, syphilis), Ampicillin/Amoxicillin (+ gram- coverage: H. influenzae, E. coli, Listeria), Piperacillin-tazobactam (broad spectrum including Pseudomonas + anaerobes) - Penicillinase-resistant penicillins: Dicloxacillin (oral), Oxacillin, Nafcillin (IV) → MSSA treatment (not MRSA) - β-lactamase inhibitors: Clavulanate, Sulbactam, Tazobactam → given with penicillins to overcome resistance - Resistance mechanisms: β-lactamase production (most common), altered PBPs (MRSA - mecA gene), porin mutations, efflux pumps - Cephalosporins (by generation): - 1st gen (Cefazolin, Cefalexin): gram+ cocci, surgical prophylaxis - 2nd gen (Cefuroxime, Cefoxitin): gram+ + some gram-, anaerobes - 3rd gen (Ceftriaxone, Cefotaxime, Ceftazidime): gram- coverage, meningitis, gonorrhea; ceftazidime covers Pseudomonas - 4th gen (Cefepime): broad including Pseudomonas - 5th gen (Ceftaroline): MRSA active - Cross-reactivity between penicillin and cephalosporins: <1-2% (share R1 side chain); can give if not anaphylaxis history - Carbapenems: Imipenem-cilastatin, Meropenem, Doripenem, Ertapenem (no Pseudomonas coverage); broadest spectrum; reserved for MDR organisms; Imipenem + cilastatin (prevents renal dehydropeptidase degradation of imipenem) - Aztreonam: monobactam; gram- only (including Pseudomonas); safe in penicillin allergy (except ceftazidime cross-reactivity) **Aminoglycosides:** - Tobramycin, Gentamicin, Amikacin, Streptomycin, Neomycin - MOA: Bind 30S ribosomal subunit → misreading of mRNA → abnormal proteins + membrane disruption; bactericidal; concentration-dependent killing - Uses: gram-negative bacilli (Pseudomonas, Enterobacteriaceae), synergy with β-lactams for enterococcal endocarditis, Streptomycin for tuberculosis - Toxicity: Nephrotoxicity (reversible, dose-related, monitor creatinine), Ototoxicity (irreversible - both vestibular and cochlear - do NOT give with loop diuretics), Neuromuscular blockade (avoid in myasthenia gravis) - Monitoring: Peak (efficacy) and Trough (toxicity) levels - NOT absorbed orally (used orally only for bowel decontamination - Neomycin) **Macrolides:** - Azithromycin (Z-pack), Clarithromycin, Erythromycin - MOA: Bind 50S ribosomal subunit (23S rRNA) → inhibit translocation; bacteriostatic - Uses: Atypical pneumonia (Mycoplasma, Legionella, Chlamydia), CAP, H. pylori (clarithromycin), MAC prophylaxis in HIV (azithromycin), whooping cough (azithromycin preferred), STIs (Chlamydia - azithromycin single dose) - Side effects: GI side effects (nausea, vomiting, diarrhea - most common with erythromycin; erythromycin is a motilin receptor agonist used in gastroparesis), QT prolongation (azithromycin, clarithromycin), hepatotoxicity (erythromycin estolate - esp. in pregnancy), ototoxicity (high-dose erythromycin) - Drug interactions: Clarithromycin inhibits CYP3A4; interactions with statins, warfarin **Fluoroquinolones:** - Ciprofloxacin, Levofloxacin, Moxifloxacin, Norfloxacin - MOA: Inhibit DNA gyrase (topoisomerase II, gram-) and topoisomerase IV (gram+) → prevent DNA supercoil relaxation → DNA strand breaks; bactericidal; concentration-dependent - Uses: UTIs (ciprofloxacin), respiratory infections (levofloxacin, moxifloxacin - "respiratory quinolones"), anthrax prophylaxis/treatment (ciprofloxacin), traveler's diarrhea, gonorrhea (resistance increasing) - Side effects: Tendinopathy/tendon rupture (Achilles tendon - especially in elderly, steroids, renal failure), cartilage damage (avoid in children, pregnancy), QT prolongation, CNS effects (dizziness, headache, seizures in susceptible), photosensitivity, peripheral neuropathy - Chelation: avoid with antacids, dairy, calcium, iron, zinc (↓absorption) - Moxifloxacin: NO renal excretion (do not use for UTI); anaerobic coverage **Tetracyclines:** - Tetracycline, Doxycycline, Minocycline, Tigecycline (glycylcycline) - MOA: Bind 30S ribosomal subunit → inhibit aminoacyl-tRNA binding → inhibit protein synthesis; bacteriostatic - Uses: Chlamydia (doxycycline DOC), Rocky Mountain Spotted Fever (doxycycline DOC), Lyme disease (doxycycline), brucellosis, cholera, malaria prophylaxis (doxycycline), acne (topical + oral), H. pylori (tetracycline in quadruple therapy), MRSA (doxycycline/minocycline for mild community MRSA) - Side effects: GI upset, esophageal ulceration (take with water, stay upright), tooth discoloration and growth retardation in children (contraindicated <8 years), teratogenic (Category D), photosensitivity, Fanconi syndrome (degraded tetracyclines), vestibular toxicity (minocycline), pseudotumor cerebri - Chelation: NOT taken with milk, antacids, iron, Ca2+ (↓absorption by 50%); Doxycycline absorption less affected by food than other tetracyclines - Tigecycline: overcomes efflux pump and ribosomal protection resistance; MDR organism coverage; no Pseudomonas/Proteus; serious infections only (IV) **Other Antibiotics:** - Vancomycin: glycopeptide; inhibits cell wall synthesis (binds D-Ala-D-Ala terminus, different site than penicillin); bactericidal; IV for MRSA, C. diff (oral vancomycin); "Red man syndrome" (with rapid infusion → histamine release, not allergy) → slow infusion + pretreat with antihistamine; nephrotoxicity + ototoxicity - Clindamycin: 50S ribosome; anaerobic infections, dental infections, aspiration pneumonia, skin/soft tissue (MRSA), bacterial vaginosis; C. diff colitis risk - Metronidazole: forms free radicals inside anaerobes/protozoa → DNA damage; bactericidal for anaerobes; also antiprotozoal (Giardia, Trichomonas, Entamoeba); C. diff (oral, first-line for mild/moderate), H. pylori (triple therapy); disulfiram-like reaction with alcohol; metallic taste; peripheral neuropathy (prolonged use) - Linezolid: oxazolidinone; 50S (23S rRNA); bacteriostatic; MRSA, VRE; serotonin syndrome risk (MAO inhibitor); reversible myelosuppression (prolonged use); lactic acidosis - Daptomycin: lipopeptide; inserts into bacterial cell membrane → depolarization → inhibits DNA/RNA/protein synthesis; bactericidal; gram+ only; NOT used for pulmonary infections (inactivated by surfactant); MRSA/VRE bacteremia and endocarditis; causes myopathy (check CPK) - Colistin/Polymyxins: lipopeptide; disrupt gram-negative outer membrane; last resort for MDR gram-negative infections (Acinetobacter, Pseudomonas, Klebsiella - carbapenem-resistant); nephrotoxic + neurotoxic **Antifungals:** - Azoles: Fluconazole, Itraconazole, Voriconazole, Posaconazole, Ketoconazole; MOA: inhibit 14α-demethylase (lanosterol → ergosterol synthesis) → ↓ergosterol → ↑permeability of fungal membrane; fungistatic; Fluconazole (Candida - especially esophageal/vaginal/UTI, cryptococcal meningitis maintenance, coccidioidomycosis); Voriconazole (invasive Aspergillus - DOC); Itraconazole (Blastomyces, Histoplasma, Sporothrix); Drug interactions: potent CYP3A4 inhibitors - Amphotericin B: polyene; binds ergosterol → pores in fungal membrane → cell leakage; fungicidal; broadest spectrum; IV only; used for invasive fungal infections (Cryptococcus meningitis induction, Aspergillus, Mucor, Candida); nephrotoxic (↓GFR, hypokalemia, hypomagnesemia → hydrate before infusion), infusion reactions ("shake and bake" - fever, chills, rigors → premedicate with acetaminophen + diphenhydramine) - Echinocandins: Caspofungin, Micafungin, Anidulafungin; MOA: inhibit β-(1,3)-D-glucan synthase → ↓cell wall glucan; fungicidal for Candida, fungistatic for Aspergillus; good safety profile; IV only; used for invasive Candidiasis especially in immunocompromised/ICU patients; active against biofilm-forming Candida - Flucytosine: converted to 5-FU inside fungi → inhibits thymidylate synthase + RNA synthesis; used in combination with Amphotericin B for Cryptococcal meningitis induction; bone marrow suppression; GI side effects - Griseofulvin: disrupts microtubules → inhibits mitosis; used for dermatophyte infections (tinea capitis - DOC in children), nail infections; given with fatty meal (↑absorption); teratogenic; induces CYP450 - Terbinafine: allylamine; inhibits squalene epoxidase → ↓ergosterol + ↑squalene accumulation; fungicidal; oral/topical; dermatophytes and onychomycosis (nail infections DOC - superior to itraconazole) **Antivirals:** - Nucleoside/Nucleotide Analogues (NAs): Acyclovir (HSV/VZV - phosphorylated by viral thymidine kinase; poor oral bioavailability; Valacyclovir has better oral bioavailability), Ganciclovir (CMV - myelosuppressive; valganciclovir oral prodrug), Foscarnet (CMV + acyclovir-resistant HSV; nephrotoxic; direct viral DNA polymerase inhibitor - not a NA), Cidofovir (CMV; nephrotoxic), Oseltamivir (Tamiflu - neuraminidase inhibitor for Influenza A/B; given within 48h) - HIV antiretrovirals: NRTIs (tenofovir, emtricitabine, abacavir, lamivudine), NNRTIs (efavirenz, nevirapine), Protease inhibitors (ritonavir used to boost other PIs - CYP3A4 inhibitor), Integrase inhibitors (dolutegravir, raltegravir), Entry inhibitors (enfuvirtide, maraviroc); HAART/cART: combination therapy to prevent resistance - Hepatitis B: Tenofovir, Entecavir (first-line); Lamivudine (resistance develops); Pegylated interferon-α (finite duration treatment; immune-mediated) - Hepatitis C: Direct-acting antivirals (DAAs): NS5A inhibitors (ledipasvir, daclatasvir) + NS5B polymerase inhibitors (sofosbuvir) + NS3 protease inhibitors (simeprevir); >95% cure rates; pan-genotypic regimens: Sofosbuvir/Velpatasvir **Antiprotozoals:** - Malaria: Chloroquine (P. vivax/ovale/malariae, chloroquine-sensitive P. falciparum; MOA: ↑lysosomal pH; resistance common in P. falciparum); Artemisinin-based combination therapy (ACT - Artemether-lumefantrine) - first-line for uncomplicated P. falciparum; Primaquine (P. vivax/ovale radical cure - eradicates liver hypnozoites; causes hemolysis in G6PD deficiency); Atovaquone-proguanil (Malarone - prophylaxis + treatment); Quinine/Quinidine (severe falciparum + pregnancy) - Metronidazole: Giardia, Trichomonas, Entamoeba histolytica (intestinal + extraintestinal); see antibiotics section - Toxoplasma: Pyrimethamine + Sulfadiazine + Folinic acid; in HIV-infected patient with ring-enhancing lesions - Pneumocystis jirovecii (PCP): TMP-SMX (first-line prophylaxis + treatment); Pentamidine, Atovaquone, Dapsone (alternatives); in HIV patients with CD4 <200 - Leishmania: Sodium stibogluconate (antimonial), Miltefosine, Amphotericin B - Trypanosomiasis: Suramin/Pentamidine (African sleeping sickness, early); Melarsoprol (CNS stage, arsenic-based, highly toxic); Benznidazole/Nifurtimox (Chagas disease) **Anthelmintics:** - Benzimidazoles (Mebendazole, Albendazole): bind β-tubulin → inhibit microtubule polymerization → inhibit glucose uptake; used for roundworms, hookworms, pinworms, whipworms, hydatid disease, neurocysticercosis (albendazole preferred) - Pyrantel pamoate: depolarizing neuromuscular blocker (nicotinic agonist) → spastic paralysis of worm; roundworms, pinworms - Ivermectin: potentiates GABA-mediated Cl- influx → hyperpolarization → paralysis; Onchocerciasis (river blindness), strongyloidiasis, scabies, head lice; drug of choice for Onchocerciasis - Praziquantel: increases cell membrane permeability to Ca2+ → tegument contraction/vacuolization → immune attack; Schistosomiasis (all species), Taenia, Diphyllobothrium; drug of choice for all trematodes and cestodes - Diethylcarbamazine (DEC): used for lymphatic filariasis, tropical eosinophilic pneumonia; MOA: unclear but immobilizes microfilariae - Niclosamide: uncouples oxidative phosphorylation in tapeworms; used for intestinal tapeworms (NOT cysticercosis - doesn't penetrate cyst); largely replaced by praziquantel --- ### SECTION 7: ENDOCRINE PHARMACOLOGY **Insulin and Antidiabetics:** Insulin types: - Ultra-rapid: Fiasp (onset 4 min), Lispro, Aspart, Glulisine (onset 15 min, duration 3-5h) → mealtime insulin - Short-acting: Regular insulin (onset 30 min, peak 2-4h, duration 6-8h) → used IV for DKA - Intermediate: NPH (onset 1-4h, peak 6-12h, duration 12-18h) - Long-acting: Glargine (onset 2-4h, peakless, duration 24h), Detemir (less predictable) - Ultra-long: Degludec (>40h duration) Oral Antidiabetics: - Metformin: Biguanide; activates AMPK → ↓hepatic gluconeogenesis; does NOT cause hypoglycemia; ↓weight; first-line T2DM; contraindicated in eGFR <30 mL/min (lactic acidosis), contrast procedures, alcohol abuse; GI side effects; ↓B12 absorption - Sulfonylureas: Glibenclamide, Glipizide, Glimepiride; close ATP-sensitive K+ channels on β cell → depolarization → Ca2+ influx → ↑insulin release; hypoglycemia risk; weight gain; second generation preferred (fewer drug interactions) - Thiazolidinediones (TZDs/glitazones): Pioglitazone, Rosiglitazone; PPARγ agonists → ↑insulin sensitivity; no hypoglycemia alone; weight gain, fluid retention, heart failure risk, bone fractures; Pioglitazone: bladder cancer risk; Rosiglitazone: cardiovascular risk (mostly withdrawn) - DPP-4 inhibitors (gliptins): Sitagliptin, Saxagliptin, Alogliptin; inhibit DPP-4 → ↑GLP-1/GIP → glucose-dependent insulin secretion; weight neutral; very safe; slight pancreatitis risk; heart failure (saxagliptin - with caution) - GLP-1 agonists: Exenatide, Liraglutide, Semaglutide, Dulaglutide; mimic GLP-1 → ↑insulin (glucose-dependent), ↓glucagon, ↓gastric emptying, ↑satiety; significant ↓weight; ↓cardiovascular events (liraglutide, semaglutide); GI side effects (nausea, vomiting - most common); pancreatitis; thyroid C-cell tumors (avoid in MEN2, family history medullary thyroid cancer); injectable (semaglutide also oral) - SGLT2 inhibitors: Dapagliflozin, Empagliflozin, Canagliflozin; block renal SGLT2 → ↑glucosuria; ↓blood glucose, ↓weight, ↓BP; cardiorenal protective (↓HF hospitalizations, ↓CKD progression); UTIs and genital mycotic infections; DKA (euglycemic DKA); Fournier's gangrene; amputation risk (canagliflozin); avoid if eGFR <30 - α-glucosidase inhibitors: Acarbose, Miglitol; inhibit intestinal glucosidases → ↓glucose absorption (slow carbohydrate digestion); GI flatulence, diarrhea; hypoglycemia alone rare but if occurs treat with glucose (not sucrose) - Meglitinides: Repaglinide, Nateglinide; similar to sulfonylureas (close K+ ATP channels) but shorter acting; take before meals; flexible dosing **Thyroid Pharmacology:** - Hypothyroidism treatment: Levothyroxine (T4) - synthetic; once daily; monitor TSH; drug interactions: antacids, calcium, iron (↓absorption → take 4h apart); T4 has long half-life (~7 days); liothyronine (T3) for myxedema coma - Antithyroid drugs: - Propylthiouracil (PTU): inhibits thyroid peroxidase (TPO) → ↓synthesis of T3/T4 PLUS inhibits peripheral conversion of T4→T3 (preferred in thyroid storm and 1st trimester pregnancy); hepatotoxicity risk (monitor LFTs) - Carbimazole/Methimazole: inhibits TPO only (NOT peripheral conversion); once daily; preferred except pregnancy 1st trimester (teratogenic); agranulocytosis (tell patient to report sore throat → check WBC) - Radioactive Iodine (I-131): ablative therapy for Graves disease/hyperthyroidism; contraindicated in pregnancy; use with caution in ophthalmopathy (may worsen) - Lugol's iodine: high dose iodide → transiently ↓thyroid vascularity and hormone release (Wolff-Chaikoff effect); used pre-operatively before thyroidectomy; thyroid storm - Propranolol (β-blocker): symptomatic relief of hyperthyroidism (tachycardia, tremor) + blocks T4→T3 conversion; thyroid storm management - Calcitonin and bone: Calcitonin → ↓osteoclast activity → ↓Ca2+ from bone; used in hypercalcemia, Paget disease, osteoporosis (nasal spray) - Bisphosphonates: Alendronate, Risedronate, Zoledronic acid; bind hydroxyapatite → inhibit osteoclast activity; used for osteoporosis, Paget disease, hypercalcemia of malignancy, bone metastases; esophageal irritation (take with full glass of water, remain upright 30 min); osteonecrosis of jaw, atypical femoral fractures (prolonged use) - PTH analogs: Teriparatide (recombinant PTH 1-34) → ↑osteoblast activity; anabolic agent; for severe osteoporosis (patients who failed bisphosphonates); Black box warning for osteosarcoma in rats; Abaloparatide (PTHrP analog) **Corticosteroids:** - MOA: bind intracellular glucocorticoid receptor → gene transcription → ↑anti-inflammatory proteins (lipocortin → ↓phospholipase A2 → ↓arachidonic acid → ↓prostaglandins/leukotrienes) + ↓pro-inflammatory cytokines; also direct membrane effects - Agents: Hydrocortisone (100%), Prednisone/Prednisolone, Methylprednisolone, Dexamethasone (no mineralocorticoid effect - preferred in cerebral edema, nausea, fetal lung maturity), Fludrocortisone (primarily mineralocorticoid - Addison disease replacement) - Uses: Asthma/COPD exacerbation, allergic reactions, anaphylaxis (secondary), autoimmune diseases, transplant rejection, adrenal insufficiency, septic shock (controversial), cerebral edema (dexamethasone), fetal lung maturation (betamethasone/dexamethasone before preterm delivery), meningitis (reduce inflammation) - Side effects: Hyperglycemia, hypertension, osteoporosis, Cushing's syndrome (weight gain, moon face, buffalo hump, striae, acne), immunosuppression, peptic ulcers (with NSAIDs risk), HPA axis suppression (do NOT stop abruptly), cataracts, glaucoma, growth retardation in children, psychiatric effects (euphoria, psychosis) - Mineralocorticoid effects: Na+ retention, K+ excretion, ↑BP; Fludrocortisone is most potent **Sex Hormones and Contraceptives:** - Estrogens: Estradiol (most potent endogenous), Ethinyl estradiol (oral contraceptives); uses: menopause HRT, contraception, primary hypogonadism; side effects: thrombosis (DVT/PE), nausea, breast tenderness, endometrial hyperplasia (without progestin) - Progestins: Progesterone, Norethindrone, Levonorgestrel, Medroxyprogesterone; combined with estrogen; prevent endometrial hyperplasia - Combined oral contraceptives (COCs): estrogen + progestin; MOA: ↑LH/FSH surge inhibition → ↓ovulation + cervical mucus thickening + endometrial changes; CI: smokers >35y, DVT/PE history, stroke, CAD, migraine with aura, breast cancer, pregnancy, uncontrolled HTN; reduces risk of ovarian cancer and endometrial cancer - Progestin-only pill ("mini-pill"): Norethindrone; does not reliably inhibit ovulation; thickens cervical mucus; used when estrogen contraindicated (breastfeeding, VTE risk) - Emergency contraception: Levonorgestrel (Plan B; within 72h, up to 120h), Ulipristal acetate (more effective up to 120h), Copper IUD (most effective, within 120h) - SERMs: Tamoxifen (ER antagonist in breast, agonist in bone/uterus → used in ER+ breast cancer; endometrial cancer risk); Raloxifene (ER antagonist in breast + uterus, agonist in bone → used for osteoporosis; no endometrial cancer risk); Clomiphene (ER antagonist in hypothalamus → ↑GnRH → ↑FSH/LH → ↑ovulation → used for infertility) - Androgens: Testosterone, Methyltestosterone; hypogonadism, wasting syndromes; anabolic steroids (abuse) - Anti-androgens: Finasteride (5α-reductase inhibitor → ↓DHT → BPH + male pattern baldness); Flutamide/Bicalutamide (AR blockers → prostate cancer); Spironolactone (AR antagonist + aldosterone antagonist); Cyproterone acetate (AR antagonist + anti-gonadotropin) --- ## PDF Generation Script Instructions Write a COMPLETE Python script using reportlab to generate this PDF. The script must: 1. Create all 7 sections with proper headings, subheadings 2. Include properly formatted tables for each drug class 3. Include Clinical Pearl boxes (light blue background) 4. Include Mnemonic boxes (light yellow background) 5. Include Q&A sections at the end of each system 6. Include a professional title page with the following info: - Title: "MBBS Pharmacology - Complete Study Guide" - Subtitle: "All Systems: ANS | CNS | CVS | Renal | Antimicrobials | Endocrine" - Based on: Katzung, Lippincott Illustrated Reviews, Goodman & Gilman's 7. Include a table of contents page 8. Generate the file at: /home/daytona/workspace/mbbs-pharmacology/MBBS_Pharmacology_Complete.pdf Write the COMPLETE script to /home/daytona/workspace/mbbs-pharmacology/generate_pharma_pdf.py, then execute it. The script should be very thorough - at least 600+ lines of Python code, covering all the content above in full detail. Make sure to test that the file was created successfully and report the final file size and path. Return: The exact file path of the generated PDF and its size in MB.

mkdir -p /home/daytona/workspace/mbbs-pharmacology && echo "Directory created" &…